Managing pollution from antibiotics manufacturing: charting actors, incentives and disincentives
Tóm tắt
Emissions of high concentrations of antibiotics from manufacturing sites select for resistant bacteria and may contribute to the emergence of new forms of resistance in pathogens. Many scientists, industry, policy makers and other stakeholders recognize such pollution as an unnecessary and unacceptable risk to global public health. An attempt to assess and reduce such discharges, however, quickly meets with complex realities that need to be understood to identify effective ways to move forward. This paper charts relevant key actor-types, their main stakes and interests, incentives that can motivate them to act to improve the situation, as well as disincentives that may undermine such motivation. The actor types and their respective interests have been identified using research literature, publicly available documents, websites, and the knowledge of the authors. Thirty-three different actor-types were identified, representing e.g. commercial actors, public agencies, states and international institutions. These are in complex ways connected by interests that sometimes may conflict and sometimes pull in the same direction. Some actor types can act to create incentives and disincentives for others in this area. The analysis demonstrates and clarifies the challenges in addressing industrial emissions of antibiotics, notably the complexity of the relations between different types of actors, their international dependency and the need for transparency. The analysis however also suggests possible ways of initiating incentive-chains to eventually improve the prospects of motivating industry to reduce emissions. High-resource consumer states, especially in multinational cooperation, hold a key position to initiate such chains.
Tài liệu tham khảo
Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13(12):1057–98.
Ashbolt NJ, Amézquita A, Backhaus T, Borriello P, Brandt KK, Collignon P, Coors A, Finley R, Gaze WH, Heberer T, Lawrence JR. Human health risk assessment (HHRA) for environmental development and transfer of antibiotic resistance. Environ Health Perspect. 2013;121(9):993–1001.
Pruden A, Larsson DJ, Amézquita A, Collignon P, Brandt KK, Graham DW, Lazorchak JM, Suzuki S, Silley P, Snape JR, Topp E. Management options for reducing the release of antibiotics and antibiotic resistance genes to the environment. Environ Health Perspect. 2013;121(8):878–85.
WHO, Global action plan on antimicrobial resistance (2015). http://www.who.int/antimicrobial-resistance/publications/global-action-plan/en.
Robinson TP, Bu DP, Carrique-Mas J, Fèvre EM, Gilbert M, Grace D, Hay SI, Jiwakanon J, Kakkar M, Kariuki S, Laxminarayan R. Antibiotic resistance is the quintessential one health issue. Trans R Soc Trop Med Hyg. 2016;110(7):377–80.
Larsson DGJ, Andremont A, Bengtsson-Palme J, Koefoed Brandt K, de Roda Husman AM, Fagerstedt P, Fick J, Flach CF, Gaze WH, Kuroda M, Kvint K, Laxminarayan R, Manaia CM, Nielsen KM, Plant L, Ploy MC, Segovia C, Simonet P, Smalla K, Snape J, Topp E, van Hengel A, Verner-Jeffreys DW, Virta MPJ, Wellington EM, Wernersson AS. Critical knowledge gaps and research needs related to the environmental dimensions of antibiotic resistance. Environ Int. 2018;117:132–8.
McEwen SA, Collignon PJ. Antimicrobial Resistance: a One Health Perspective. Microbiology spectrum. 2018;6(2). https://doi.org/10.1128/microbiolspec.ARBA-0009-2017.
Bengtsson-Palme J, Kristiansson E, Larsson DJ. Environmental factors influencing the development and spread of antibiotic resistance. FEMS Microbiol Rev 2017 24;42(1): https://doi.org/10.1093/femsre/fux053.
Karkman A, Pärnänen K, Larsson DJ. Fecal pollution can explain antibiotic resistance gene abundances in anthropogenically impacted environments. Nat Commun. 2019;10(1):80.
Larsson DJ. Pollution from drug manufacturing: review and perspectives. Philos Trans Royal Soc B: Biol Sci. 2014;369(1656):20130571.
Initiatives for Addressing Antimicrobial Resistance in the Environment: Current Situation and Challenges (2018). https://wellcome.ac.uk/sites/default/files/ antimicrobial-resistance-environment -report.pdf. Accessed 22 Mar 2019.
O’Neill J. Review on antimicrobial resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations 2014 11.
AMR Industry Alliance. https://www.amrindustryalliance.org. Accessed 22 Mar 2019.
Access to Medicines Foundation Antimicrobial Resistance Benchmark 2018. https://accesstomedicinefoundation.org/media/atmf/2017-Methodology-for-2018-Antimicrobial-Resistance-Benchmark-final.pdf.
Government of India. National Action Plan on Antimicrobial Resistance (NAP-AMR) 2017–2021. http://www.searo.who.int/india/topics/antimicrobial_resistance/nap_amr.pdf. Accessed 22 Mar 2019.
Tomson G, Vlad I. The need to look at antibiotic resistance from a health systems perspective. Upsala J Med Sci. 2014;119(2):117–24.
Ågerstrand M, Berg C, Björlenius B, Breitholtz M, Brunström B, Fick J, Gunnarsson L, Larsson DJ, Sumpter JP, Tysklind M, Rudén C. Improving environmental risk assessment of human pharmaceuticals. Environ Sci Technol. 2015;49(9):5336–45.
Larsson DJ, Fick J. Transparency throughout the production chain—a way to reduce pollution from the manufacturing of pharmaceuticals? Regul Toxicol Pharmacol. 2009;53(3):161–3 https://doi.org/10.1016/j.yrtph.2009.01.008.
Berendonk TU, Manaia CM, Merlin C, Fatta-Kassinos D, Cytryn E, Walsh F, Bürgmann H, Sørum H, Norström M, Pons MN, Kreuzinger N. Tackling antibiotic resistance: the environmental framework. Nat Rev Microbiol. 2015;13(5):310 https://doi.org/10.1038/nrmicro3439.
Bengtsson-Palme J, Gunnarsson L, Larsson DJ. Can branding and price of pharmaceuticals guide informed choices towards improved pollution control during manufacturing? J Clean Prod. 2018;171:137–46 https://doi.org/10.1016/j.jclepro.2017.09.247.
Graafland J, Van de Ven B. Strategic and moral motivation for corporate social responsibility. J Corp Citizsh. 2006;22:111-123.
Wasserman, Stanley, and Katherine Faust. Social network analysis: Methods and applications. Vol. 8. Cambridge: Cambridge university press; 1994.
Scott, J. Social network analysis. Sociology. 1988;22(1):109-127.
Yale Center for Environmental Law & Policy, Global metrics for the environment: Ranking country performance on high-priority environmental issues. Yale University, 2018. https://epi.envirocenter.yale.edu/downloads/epi2018policymakerssummaryv01.pdf. Accessed 19 Sept 2019.
LIF (Swedish Association of the Pharmaceutical Industry). Ethical Rules For The Pharmaceutical Industry In Sweden (2017). https://www.lif.se/globalassets/etik/dokument/ler-english-20180212-rp.pdf. Accessed 22 Mar 2019.
González-Plaza JJ, et al. Antibiotic-manufacturing sites are hot-spots for the release and spread of antibiotic resistance genes and mobile genetic elements in receiving aquatic environments. Environ Int. 2019;130:104735.
Bengtsson-Palme J, Larsson DJ. Concentrations of antibiotics predicted to select for resistant bacteria: proposed limits for environmental regulation. Environ Int. 2016;86:140–9 https://doi.org/10.1016/j.envint.2015.10.015.
Le Page G, Gunnarsson L, Snape J, Tyler CR. Integrating human and environmental health in antibiotic risk assessment: a critical analysis of protection goals, species sensitivity and antimicrobial resistance. Environ Int. 2017;109:155–69.
WHO, European Commission: China policies to promote local production of pharmaceutical products and protect public health: http://www.who.int/phi/publications/2081China020517.pdf. Accessed 24 Apr 2019.
Ghafur, Abdul, State-Level AMR Action Plans In India: Progress At A Snail’s Pace! AMR Control: http://resistancecontrol.info/wp-content/uploads/2018/05/22-25.pdf.
Reputation Institute: https://www.reputationinstitute.com. Accessed 22 Mar 2019.
Sandberg J. Changing the world through shareholder activism? Etikk i praksis-Nordic J Appl Ethics. 2011;1(1):51–78.
Jeucken, Marcel. Sustainability in finance: banking on the planet. Eburon Uitgeverij BV, 2004.
European Medicines Agency, Authorisation of Medicines: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000109.jsp. Accessed 22 Mar 2019.
Nijsingh et al., Justifying Antibiotic Resistance Interventions: Uncertainty, Precaution and Ethics. In: Jamrozik, E., & Selgelid, M. J., Ethics and Drug Resistance: Collective Responsibility for Global Public Health. Springer, Cham, 2019.
Medical Products Agency, Platform to enable the initiation of a revision of EU legislation on Good Manufacturing Practice, GMP, in order for legislation also to comprehend environmental considerations. https://lakemedelsverket.se/upload/om-lakemedelsverket/rapporter/Platform-to-enable-the-initiation-of-a-revision-of-EU-legislation-on-GMP-in-order-for-legislation-also-to-comprehend-environmental-considerations.pdf. Accessed 22 Mar 2019.
European Commission, A European one health action plan against antimicrobial resistance (AMR) (2017): https://ec.europa.eu/health/amr/action_eu_en.
O’Neill J. Tackling drug-resistant infections globally: final report and recommendations; 2016.
Lagercrantz, Kedjorna Vill ta täten i miljöfrågan (2017), Dagens Medicin: https://www.dagensmedicin.se/artiklar/2017/03/01/kedjorna-vill-ta-taten-i-miljofragan.
Dar OA, Hasan R, Schlundt J, Harbarth S, Caleo G, Dar FK, Littmann J, Rweyemamu M, Buckley EJ, Shahid M, Kock R. exploring the evidence base for national and regional policy interventions to combat resistance. Lancet. 2016;387(10015):285–95.
European Commission, European Union Strategic Approach to Pharmaceuticals in the Environment (11-03-2019): http://ec.europa.eu/environment/water/water-dangersub/pdf/strategic_approach_pharmaceuticals_env.PDF. Accessed 21 Oct 2019.
Läkemedelsverket. Läkemedel i miljön. Report Dnr: 4.3.1–2018-048910. Uppsala: Läkemedelsverket; 2018.
Statens Offentliga Utredningar, Ersättning vid läkemedelsskador och miljöhänsyn i läkemedelsförmånerna (2013): https://www.regeringen.se/49b69c/contentassets/6fdcaa7adf8442b0a22883719115deeb/ersattning-vid-lakemedelsskador-och-miljohansyn-i-lakemedelsformanerna-sou-2013.23-del-1.
Swedish Medical Products Agency, Comments on the List of Substitutable Medicinal Products: https://lakemedelsverket.se/english/product/Medicinal-products/Substitution.
Lag (2002:160) om läkemedelsförmåner m.m. Online: https://www.riksdagen.se/sv/dokument-lagar/dokument/svensk-forfattningssamling/lag-2002160-om-lakemedelsformaner-mm_sfs-2002-160. Accessed 21 Oct 2019.
Pharmaceutical Supply Chain Initiative: https://www.bsr.org/en/collaboration/groups/pharmaceutical-supply-chain-initiative). Accessed 22 Mar 2019.
Årdal, Christine et al., An antibiotic’s journey from marketing authorization to use, Norway: https://www.who.int/bulletin/volumes/95/3/16-172874/en. Accessed 22 Mar 2019.
UNDP, Sustainable Procurement of Pharmaceuticals: https://noharm-europe.org/sites/default/files/documents-files/4836/3.%20Lorea%20Coronado-Garcia.pdf. Accessed 22 Mar 2019.
Janusinfo, Frågor och svar om NT-rådet och hälsoekonomi: https://janusinfo.se/nationelltordnatinforande/saarbetarvi/rollerochkontaktuppgifter/roller/ntradetnyaterapier/fragorochsvaromntradetochhalsoekonomi.4.4771ab7716298ed82bab552.html. Accessed 22 Mar 2019.
Sandler T. Global challenges: an approach to environmental, political, and economic problems. Cambridge: Cambridge University Press; 1997.
Sandler T. Overcoming global and regional collective action impediments. Global Policy. 2010;1(1):40–50.